I’ll just start off by telling you that yes, this stock might be one of the most familiar biotech ideas we’ve ever covered here at Stock Gumshoe — not necessarily because I like it or our other writers like it, or even because it’s been a good investment, but because it’s been so aggressively teased […]
Articles
Today we’ve got a two-fer — two different big publishers are teasing different “liquid biopsy” stocks, and I’m no expert on the technology or the prospects for this diagnostic “trend” that we’ve been hearing more about… so I’ll just sift the clues, identify the companies, and let you chatter about their merits amongst yourselves. The […]
Ridiculously huge gains are nothing new in biotech — they may not come easy, but they are sorely tempting… and, unlike with most “boring” companies that have ongoing businesses and have to build and compound to create lasting wealth, they can create fantastical gains almost overnight on the strength of a breakthrough clinical trial result […]
Medical technology is always a prime area for investor excitement — we love the idea of a company that can make things bigger, cheaper, stronger, faster in any field of human endeavor, but somehow the idea of a company doing it in medicine, where we can feel both wealthy and virtuous after investing, is even […]
I’ve got a few thoughts for you on some companies I follow and own, and a little follow-up on last week’s chatter about hedge funds, but first I thought you’d like a quick teaser solution for your Friday File fun… The pitch is for Stephen Petranek’s Breakthrough Technology Alert — there’s been some discussion recently […]
Who can resist an entreaty like that? Several intrepid Gumshoe readers sent along pleas for a solution to this one today … and we are, as always, happy to oblige. I know you have a choice when it comes to blathering internet chatterboxes, and I want to thank you for choosing this one today. The […]
Focuses on companies with hot new technologies, including biotech and technology stocks. Formerly run by Patrick Cox, who moved on to launch Transformational Technology Alert, a similar letter for Mauldin Economics, and Stephen Petranek and Gerald Celente have also briefly helmed this letter.
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
This was a fantastic letter and an incredible bargain at 79$ per year. A real shame he closed it down. However, for sign...
Howard Lindzon sent out a note to those of us who subscribed and said that he's discontinuing the newsletter as it was m...
That's what I'm seeing on the CDC site too - diabetes. And Eli Lilly bought a glucagon nasal spray from a small company ...
And now Citron has turned against Twitter (TWTR) at ~$30-32, after being bullish somewhere in the $22-24 range back in J...